Located in Xiamen, China, 厦门致善生物科技股份有限公司 is a leading biotechnology company specializing in the development, production, sales, and service of molecular diagnostic reagents and instruments. The company is dedicated to researching global cutting-edge nucleic acid detection technology and providing innovative solutions that contribute to early disease detection, precise treatment, and prognosis monitoring. With the goal of becoming a global leader in nucleic acid testing, 厦门致善生物科技股份有限公司 aims to make nucleic acid testing technology accessible to the public, thus improving the quality of human life.

Guided by their core values of scientific exploration, innovation, integrity, quality, fairness, cooperation, excellence, and benevolence, the company holds several international patents in the fields of in-vitro diagnostic material preparation, ultrafine magnetic particle nucleic acid extraction, homogeneous PCR multi-target nucleic acid testing, and automated instrument systems. Certified with ISO13485 quality management system, 厦门致善生物科技股份有限公司 continuously strives to ensure that their products meet market demands and deliver professional and high-quality services. Additionally, the company's commitment to social responsibility is evident through their dedication to creating value for customers while strengthening their role in society.

In 2021, the establishment of 厦门致善医检独立医学检验所 (Xiamen Zhishan Medical Testing Institute) will support more medical institutions in conducting advanced molecular diagnostic projects. Over the years, the company has received numerous honors and recognitions, including being named a national high-tech enterprise, a Little Giant enterprise by the Ministry of Industry and Information Technology, and a leading enterprise in the field of scientific and technological innovation in Fujian Province. With their state-of-the-art technology and expertise, 厦门致善生物科技股份有限公司 continues to make significant contributions in the field of nucleic acid testing